Addition of Nancy Chang to Board Will Benefit SciClone (SCLN), Maintain Buy - Aegis
- Futures tread higher as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
SciClone Pharma (SCLN) Names Nancy Chang as Director
September 23, 2013 6:29 AM EDTSciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today announced that Nancy T. Chang, Ph.D., has been appointed a member of the Company's board of directors. Dr. Chang has more than 30 years of experience in the pharmaceutical and biotechnology industry, and has successfully developed and commercialized multiple therapeutic and diagnostic products. She is highly respected as an innovative and successful executive and director, entrepreneur, strategic advisor, investor and philanthropist. Dr. Chang received widespread acclaim for the founding and subsequent sale of Tanox to Genentech in 2007, and for changing the treatment paradigm for allergy-related asthma through the... More